

Murtuza Bharmal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1287894/publications.pdf>

Version: 2024-02-01

42
papers

1,688
citations

471061

17
h-index

288905

40
g-index

44
all docs

44
docs citations

44
times ranked

2535
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 114-122.	0.9	3
2	How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma Treatments. <i>Value in Health</i> , 2021, 24, 1137-1144.	0.1	2
3	Systematic literature review of current treatments for stage III Merkel cell carcinoma. <i>Future Oncology</i> , 2021, 17, 4813-4822.	1.1	5
4	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. <i>Applied Health Economics and Health Policy</i> , 2021, 19, 389-401.	1.0	3
5	Health-related quality of life trajectory of treatment-naïve patients with Merkel cell carcinoma receiving avelumab. <i>Future Oncology</i> , 2020, 16, 2089-2099.	1.1	2
6	Update on the psychometric properties and minimal important difference (MID) thresholds of the FACT-M questionnaire for use in treatment-naïve and previously treated patients with metastatic Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 145.	1.0	6
7	Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. <i>BMC Medical Research Methodology</i> , 2020, 20, 103.	1.4	10
8	Patient Experiences with Avelumab in Treatment-Naïve Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial. <i>Patient</i> , 2020, 13, 457-467.	1.1	11
9	Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway) Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 645-656.	0.7	1
10	Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab. <i>Advances in Therapy</i> , 2019, 36, 2327-2341.	1.3	8
11	Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma. <i>Value in Health</i> , 2019, 22, 1170-1177.	0.1	2
12	Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma. <i>Pharmacoeconomics - Open</i> , 2019, 3, 377-390.	0.9	20
13	Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 349-359.	0.7	4
14	Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 609-618.	2.0	21
15	Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 659-672.	0.7	2
16	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2018, 14, 255-266.	1.1	22
17	Living with Merkel Cell Carcinoma (MCC): Development of a Conceptual Model of MCC Based on Patient Experiences. <i>Patient</i> , 2018, 11, 439-449.	1.1	9
18	How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 95.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: innovative use of patient insights. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 881-890.	0.6	6
20	Treatment patterns, comorbidities, healthcare resource use, and associated costs by line of chemotherapy and level of comorbidity in patients with newly-diagnosed Merkel cell carcinoma in the United States. <i>Journal of Medical Economics</i> , 2018, 21, 1159-1171.	1.0	4
21	Using Response Evaluation Criteria in Solid Tumors in real-world evidence cancer research. <i>Future Oncology</i> , 2018, 14, 2841-2848.	1.1	17
22	Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. <i>Future Oncology</i> , 2017, 13, 1699-1710.	1.1	98
23	Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 1263-1279.	1.1	113
24	Merkel cell carcinoma: Epidemiology, prognosis, therapy and unmet medical needs. <i>European Journal of Cancer</i> , 2017, 71, 53-69.	1.3	307
25	Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2017, 15, 247.	1.0	14
26	Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe. <i>Oncotarget</i> , 2017, 8, 79731-79741.	0.8	77
27	Incremental Dementia-Related Expenditures in a Medicaid Population. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 73-83.	0.6	18
28	Development and validation of a Subjective Post Sleep Diary (SPSD) to assess sleep status in subjects with Restless Legs Syndrome. <i>Sleep Medicine</i> , 2011, 12, 704-710.	0.8	9
29	Prevalence and disease burden of primary restless legs syndrome: Results of a general population survey in the United States. <i>Movement Disorders</i> , 2011, 26, 114-120.	2.2	187
30	Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. <i>BMC Neurology</i> , 2011, 11, 48.	0.8	13
31	Patient preferences for adherence enhancing tools. <i>Journal of Communication in Healthcare</i> , 2010, 3, 266-278.	0.8	14
32	Validation of a Women's Sexual Interest Diagnostic Interview Short Form (WSID-SF) and a Daily Log of Sexual Activities (DLSA) in Postmenopausal Women with Hypoactive Sexual Desire Disorder. <i>Journal of Sexual Medicine</i> , 2010, 7, 917-927.	0.3	14
33	Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. <i>Health and Quality of Life Outcomes</i> , 2009, 7, 36.	1.0	200
34	Budget Impact Analysis of Rapid Screening for <i>Staphylococcus aureus</i> Colonization Among Patients Undergoing Elective Surgery in US Hospitals. <i>Infection Control and Hospital Epidemiology</i> , 2008, 29, 16-24.	1.0	23
35	Resource utilisation, charges and mortality following hospital inpatient admission for congestive heart failure among the elderly in the US. <i>Journal of Medical Economics</i> , 2008, 11, 397-414.	1.0	11
36	National Trends in <i>Staphylococcus aureus</i> Infection Rates: Impact on Economic Burden and Mortality over a 6-Year Period (1998-2003). <i>Clinical Infectious Diseases</i> , 2007, 45, 1132-1140.	2.9	166

#	ARTICLE	IF	CITATIONS
37	Comparing the EQ-5D and the SF-6D Descriptive Systems to Assess Their Ceiling Effects in the US General Population. <i>Value in Health</i> , 2006, 9, 262-271.	0.1	156
38	Survey of pharmacist collaborative drug therapy management in hospitals. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 2489-2499.	0.5	23
39	Health Insurance Coverage and Health-Related Quality of Life: Analysis of 2000 Medical Expenditure Panel Survey Data. <i>Journal of Health Care for the Poor and Underserved</i> , 2005, 16, 643-654.	0.4	25
40	Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: Comparison of three explicit criteria. <i>Clinical Therapeutics</i> , 2005, 27, 88-99.	1.1	45
41	Development, Validation, and Application of a Scale to Measure the Impact of the Internet on Market Structure and Competition in the Retail Pharmacy Market. <i>Journal of Pharmaceutical Marketing and Management</i> , 2003, 16, 81-99.	0.1	0
42	Impact of Internet Use on Business Functions in Independent Community Pharmacies. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2003, 43, 720-724.	0.7	0